Business Description
BioXcel Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US09075P1057
Description
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.64 | |||||
| Equity-to-Asset | -0.77 | |||||
| Debt-to-Equity | -1.79 | |||||
| Debt-to-EBITDA | -0.61 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -17.51 | |||||
| Beneish M-Score | 2.24 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -14.5 | |||||
| 3-Year EPS without NRI Growth Rate | -16.6 | |||||
| 3-Year FCF Growth Rate | -20.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 191.72 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.44 | |||||
| 9-Day RSI | 47.96 | |||||
| 14-Day RSI | 47.27 | |||||
| 6-1 Month Momentum % | -10.64 | |||||
| 12-1 Month Momentum % | -87.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.65 | |||||
| Quick Ratio | 2.57 | |||||
| Cash Ratio | 2.39 | |||||
| Days Inventory | 571.44 | |||||
| Days Sales Outstanding | 93.52 | |||||
| Days Payable | 3096.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7 | |||||
| Shareholder Yield % | -73.81 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 8.62 | |||||
| Operating Margin % | -12146.45 | |||||
| Net Margin % | -12974.86 | |||||
| FCF Margin % | -11259.66 | |||||
| ROE % | -2323.67 | |||||
| ROA % | -127.86 | |||||
| ROIC % | -2730.34 | |||||
| ROC (Joel Greenblatt) % | -9373.37 | |||||
| ROCE % | -154.28 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 56.04 | |||||
| EV-to-EBIT | -0.69 | |||||
| EV-to-Forward-EBIT | -1.26 | |||||
| EV-to-EBITDA | -0.7 | |||||
| EV-to-Forward-EBITDA | -1.33 | |||||
| EV-to-Revenue | 83.41 | |||||
| EV-to-Forward-Revenue | 45.54 | |||||
| EV-to-FCF | -0.76 | |||||
| Earnings Yield (Greenblatt) % | -144.91 | |||||
| FCF Yield % | -196.41 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioXcel Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.279 | ||
| EPS (TTM) (€) | -5.708 | ||
| Beta | 1.4 | ||
| Volatility % | 124.97 | ||
| 14-Day RSI | 47.27 | ||
| 14-Day ATR (€) | 0.115286 | ||
| 20-Day SMA (€) | 2.49505 | ||
| 12-1 Month Momentum % | -87.51 | ||
| 52-Week Range (€) | 1.83 - 27.6 | ||
| Shares Outstanding (Mil) | 30.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioXcel Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioXcel Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioXcel Therapeutics Inc Frequently Asked Questions
What is BioXcel Therapeutics Inc(FRA:BX2)'s stock price today?
The current price of FRA:BX2 is €2.49. The 52 week high of FRA:BX2 is €27.60 and 52 week low is €1.83.
When is next earnings date of BioXcel Therapeutics Inc(FRA:BX2)?
The next earnings date of BioXcel Therapeutics Inc(FRA:BX2) is 2024-05-08 Est..
Does BioXcel Therapeutics Inc(FRA:BX2) pay dividends? If so, how much?
BioXcel Therapeutics Inc(FRA:BX2) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers